Publication Name	World Journal of Clinical Oncology
Manuscript ID	25798
Country	Netherlands

Received	2016-03-23 08:46
Peer-Review Started	2016-03-24 11:32
To Make the First Decision	2016-05-13 16:26
Return for Revision	2016-05-16 15:47
Revised	2016-06-06 22:21
Second Decision	2016-07-20 17:05
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-08-01 16:02
Articles in Press	2016-08-01 16:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-09-28 13:17
Publish the Manuscript Online	2016-10-08 16:54

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Role of Akt signaling in resistance to DNA-targeted therapy
Manuscript Source	Invited Manuscript
All Author List	Abolfazl Avan, Ravi Narayan, Elisa Giovannetti and Godefridus J Peters
Funding Agency and Grant Number
Corresponding Author	Dr. Godefridus J Peters, PhD, Professor, Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. gj.peters@vumc.nl
Key Words	Phosphatidylinositol 3 kinase/Akt; Platinum; Taxane; Antimetabolite; Radiation
Core Tip	The Akt pathway plays an important role in resistance to several cytotoxic agents, targeted drugs and radiation. Exposure to these drugs will stimulate the Akt survival pathway leading to a decreased response to these drugs. In model systems inhibition of the Akt pathway enhanced the cytotoxicity of drugs like taxanes, antimetabolites, platinum analogs, several targeted drugs and radiation. Akt inhibitors offer a new opportunity to increase the efficacy of currently used drugs and of radiotherapy.
Publish Date	2016-10-08 16:54
Citation	Avan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol 2016; 7(5): 352-369
URL	http://www.wjgnet.com/2218-4333/full/v7/i5/352.htm
DOI	http://dx.doi.org/10.5306/wjco.v7.i5.352

Full Article (PDF)	WJCO-7-352.pdf
Full Article (Word)	WJCO-7-352.doc
Manuscript File	25798-Review.doc
Answering Reviewers	25798-Answering reviewers.pdf
Audio Core Tip	25798-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	25798-Conflict-of-interest statement.pdf
Copyright License Agreement	25798-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	25798-Language certificate.pdf
Peer-review Report	25798-Peer-review(s).pdf
Scientific Misconduct Check	25798-Scientific misconduct check.pdf
Scientific Editor Work List	25798-Scientific editor work list.pdf